Archive | October, 2021

Innovator’s Pitch Challenge Applications Due Tomorrow

21 Oct

By Megan Rychwa, Investor Research Analyst, LSN

Life Science Nation’s last conference of the year, Digital RESI November 16-18, is currently accepting applications from startup companies across the globe for the popular Innovator’s Pitch Challenge (IPC). The number of participating startups has doubled within the last year, with hundreds of companies and investors experiencing the value firsthand. Applications are accepted on a rolling basis until Friday, October 22.

The Innovator’s Pitch Challenge is an opportunity for early-stage companies to pitch to a live panel of investors within their sector. Each company’s marketing materials are highlighted on their dedicated webpage, as well as their recorded pitch, which investors can see prior to the conference in preparation for the live event. The pitch session is a unique chance for companies to gain exposure to a large investor audience and prepare those companies to build strategic partnerships with well-matched investors. The cost for IPC finalists includes event registration, as well as a $500 pitch fee.

The deadline for IPC applications is tomorrow, so make sure your application is in and you don’t miss out on this great opportunity to tell your story!

RESI-NOV-Banner-3050x-1050

Meet the Faces of Digital RESI November

21 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI November is building momentum with an all-star lineup of panelists prepared to connect on some of the biggest challenges within early-stage life science and healthcare. At each RESI, panels provide insight into the industry and what investors and key players are looking for and who they’re choosing to partner with. Learn directly from the experts, ask questions in real-time, and add them to your partnering queue.

Early bird rates end next week. Sign up today to save $100 and get early access to the partnering platform, opening Monday, October 25, to start meeting with potential partners and these faces of Digital RESI November.

Preliminary Panelists at Digital RESI November

Cynthia Cai
Venture Partner
Viva BioInnovator 		Jonathan Cohen
CEO
20/20 GeneSystems 		Ruchi Dana
Board Member
Dana Group 		Nissim Darvish
Senior Managing Director (Israel)
OrbiMed Advisors LLC
Dave Dlesk
CEO
Embrace Prevention Care 		Lana Feng
Co-Founder & CEO
HumaAI Inc 		Dave Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels 		Les Funtleyder
Healthcare Portfolio Manager
E Squared Capital
Shruti Gandhi
Founder & Managing Partner
Array Ventures 		Ernst Geutjes
Partner
Array Ventures 		Tom Gibbs
Director
Debiopharm Innovation Fund 		Kimberly Ha
Founder & CEO
KKH Advisors
Betsabeh Madani Hermann, PhD, MBA
Life Science and Healthcare Investor and Advisor		 Chihiro Hosoya
BD/VC Head, Rx+ Business Accelerator
Astellas Rx+ Business Accelerator		 Baudouin Hue
Partner
Karista		 Alyssa Jaffee
Vice President
7wire Ventures
Taha Jangda
Partner
HealthX Ventures		 Taja Lester
Managing Partner
Health Equity Capital		 Justin Leushner
Partner
Launchit Ventures		 Petra Meyer
Managing Director – HealthCare Sector Group Lead
Golden Seeds
Alex Morgan
Partner
Khosla Ventures		 Rohit Pratap Singh
Vice President, Investments
Xeraya Capital		 Rachel Scherl
CEO
SPARK Solutions for Growth		 Dennis Schmitt
Founder/CEO
Nurotech
Niels Sharman
Investment Analyst
High-Tech Gründerfonds		 Patrik Sobocki
Investment Manager Life Science
Industrifonden		 Travis Whitfill
Partner
Bios Partners		 Thierry Wurch
Senior Director
Ipsen S.A.

RESI-NOV-Banner-3050x-1050

Global Tech Hub Gathering at Digital RESI Nov. 16-18

21 Oct

By Candice He, Global Investment Strategist, LSN

As a global fundraising platform dedicated to connecting early-stage life science companies with investors and strategic partners, Life Science Nation (LSN) consistently hosts attendees from more than thirty countries at its partnering events. At Digital RESI November 16-18, we are offering two programs to accelerate Tech Hub involvement and wire them into the RESI investor community:

  • 50% discount on any RESI conference registration for early-stage constituent companies from participating Tech Hubs
  • RESI Live Agenda feature and dedicated landing page showcasing their programs
  • Group fundraising package for early-stage companies to access the LSN Investor Database ($6,995) and RESI registration ($795) with a pitch slot in the Innovator’s Pitch Challenge ($500) for only $1,500

Are you involved with a tech hub that could benefit from the RESI community? Contact us to learn more about our offerings and how we can help you reach your fundraising goals.

To help startups that are new to early-stage fundraising gain tactical partnering skills, LSN will offer two complimentary virtual Fundraising Bootcamps. The following topics will be covered in each hour-long webinar:

  • Debunking the Top 10 Myths in Early-Stage Fundraising
  • How to Get Your Global Target List of Life Science Investors
  • Partnering Strategy: Preparing for Your Investor Meetings
October 28, Thursday, 11 AM EDT Register Here
November 4, Thursday, 2 PM EDT Register Here

Partial List of Confirmed Tech Hub Participants

RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: Investment Group Capable of Investing Up to $200M, Seeks Therapeutics, Devices, Diagnostics Opportunities Across All Stages of Development

21 Oct

A large investment group with office in USA and Europe have invested in 265 companies across 55 countries. The firm is very active in the pharmaceutical and biotech industry, with around 70% of their portfolio being within these sectors. The firm has activity in listed companies, where they have interest in being a minority shareholder, with an investment size ranging from $10M to $200M. The firm is also interested in pre- IPO companies, with an investment size ranging from $5M to $200M in the form of equity, however the firm is only interested in companies that are planning on being listed in the stock exchange in the next 12 – 24 months. The firm has been successful in listing companies in the stock exchange, having done so with 4 companies so far, so their goal is to invest in companies who have that strategy. The firm is open to global opportunities.

The firm is looking for opportunities within the therapeutics, diagnostics and medical device sectors. The firm is agnostic in terms of subsector and indication, and will invest in all three classes of medical devices. The firm is open to pre-clinical companies.

The firm is open to all types of management teams with the caveat that the company must be planning on going public in the next 2 years. The firm prefers to lead investments and does not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Capital Firm Invests Up to €10M In Therapeutics & Medical Device Companies in Europe and USA

21 Oct

A life science venture capital firm based in Western Europe with an additional office in USA closed its latest fund in 2019. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €5 million-€10 million. The third fund is looking to make 10 investments. The firm’s current fund is focused on the EU but the firm also invests in the US.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused Venture Investment Fund Seeks Early and Growth-Stage Therapeutics, Devices, Research Tools, and More in USA, Europe, and China

21 Oct

A healthcare-focused venture investment fund is backed by a core investment team with members all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Clinical Stage Biopharma Seeks Global Early-Stage Therapeutics Assets to Supplement Their Existing Portfolio For Investment, In-Licensing, and More

21 Oct

A clinical stage biopharmaceutical company headquartered in China with additional offices throughout USA and China is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →